India gets first dengue vaccine as DCGI approves Takeda’s QDENGA
The Drugs Controller General of India (DCGI) approved Takeda Biopharmaceuticals' QDENGA, marking India's first dengue vaccine for individuals aged 4-60. This vaccine can be administered without pre-vaccination testing and is effective against all four dengue virus serotypes, addressing a significant public health challenge as India reports thousands of dengue cases annually. With over 32 million doses distributed globally since its 2022 launch, QDENGA's approval is a crucial step in enhancing dengue prevention efforts in India.